Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Carl Zeiss Meditec AG
Carl Zeiss Meditec makes eye-care and surgical equipment — diagnostic machines, artificial lenses, and surgical microscopes — that it sells to eye doctors, hospitals, and surgeons.
Carl Zeiss Meditec makes the tools eye doctors and surgeons use to fix and preserve people's sight. Its machines scan the eye to catch diseases like glaucoma early, its intraocular lenses replace the cloudy lens in a cataract operation, and its surgical microscopes give surgeons a magnified, steady view during delicate operations. Hospitals, clinics, and eye surgeons buy these products, often paying for the hardware plus ongoing service and software upgrades.
The company sits inside the wider Carl Zeiss group, the German optics giant famous for camera lenses and industrial measurement gear, but Meditec is its own publicly traded business focused squarely on medicine. It rose to prominence through the cataract surgery revolution: a lens implant takes about ten minutes and can restore sight to millions of older people, and Meditec sells both the lenses and the vision-measurement machines surgeons use to pick the right one. That "sell the whole package" approach is the moat. A surgeon who measures eyes with a Meditec machine and implants Meditec lenses has one throat to choke, and switching means retraining and rewiring the workflow. The same logic applies to surgical microscopes, where the brand is a byword for precision and reliability. Its main rivals are large, including Alcon in surgical eye care, Johnson & Johnson in vision products, and Bausch + Lomb in lenses, alongside Topcon and other diagnostics players.
The business is not without bruises. It is exposed to hospital spending cycles, currency swings, and a slowdown in demand for certain elective procedures, and in recent years it has had to wrestle with weaker growth in some regions and pressure in its Chinese market as healthcare spending tightened. Still, an aging population keeps pushing more people toward cataract and retina care every year, which gives the company a steady tailwind it can lean on.
Saved answer · last researched 12 Nov 2026